TYK Medicines TY-4028 —The EGFR/HER2 tyrosine kinase inhibitor approved by FDA to conduct the clinical trial

TYK Medicines will present the research progress and results of 6 innovative drug projects at the 2023 Annual Meeting of American Association for Cancer Research (AACR 2023)

TYK Medicine TY-2699a —The first CDK7 inhibitor in China approved by FDA to conduct clinical trial

TYK Medicine TY-2699a —The first CDK7 inhibitor in China approved by FDA to conduct clinical trial

TYK Medicines has Successfully Passed the Recognition for Being a Specialized and Sophisticated Small and Medium-Sized Enterprise in Zhejiang Province

Innovative Pioneer: TYK Medicines was Selected for the Elite “100 Unicorn Talents in Technology”

Innovative Pioneer: TYK Medicines was Selected for the Elite “100 Unicorn Talents in Technology”

TYK Medicines (Zhejiang) was Recognized as a High and New Technology Enterprise

According to the relevant provisions of the "Measures for the Administration of the Recognition of